-
公开(公告)号:US20140155390A1
公开(公告)日:2014-06-05
申请号:US14093812
申请日:2013-12-02
Applicant: Pfizer Inc.
Inventor: James Thomas Anderson , Eugene Lvovich Piatnitski Chekler , Edmund L. Ellsworth , Bruce Kipp Erickson , Adam Matthew Gilbert , Anthony P. Ricketts , David P. Thompson , Rayomand Jal Unwalla , Patrick Robert Verhoest
IPC: C07D417/04 , C07C255/59
CPC classification number: C07D417/04 , C07C255/58 , C07C255/59 , C07D205/04 , C07D207/08 , C07D211/22 , C07D217/26 , C07D285/10 , C07D401/04
Abstract: The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched chain alkyl,etc.; R1 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1-C6 linear or branched chain alkyl, etc.;. R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; Q is —CO—, —(CH2)q—, —(CHRs)q—, or (CRsRt)q—, where Rs and Rt are independently C1-C6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.
Abstract translation: 本发明涉及式1,2或3的化合物:其中A是N或-CR 0-,其中R 0是氢,C 1 -C 6直链或支链烷基等,Z是-CRe-或 - N-,其中Re为氢,C1-C6直链或支链烷基等; R1是氢,C1-C6直链或支链烷基等; R2独立地为氢或C1-C6直链或支链烷基; R3和R4独立地是氢,C1-C6直链或支链烷基等。 R5和R6独立地是氢或C1-C6直链或支链烷基等; R8是氢,C1-C6直链或支链烷基等; R9和R10独立地为氢或C1-C6直链或支链烷基等; Q是-CO-, - (CH 2)q - , - (CHRs)q-或(CRsRt)q-,其中R 5和R 5独立地是C 1 -C 6直链或支链烷基,芳基,烷基芳基,杂芳基或烷基杂芳基; 其中q是0,1,2或3; 并且其中n为0,1,2,3,4或5; 或其药学上可接受的盐包含含有这些化合物的组合物; 以及这些化合物在治疗各种疾病,特别是受雄激素受体影响或介导的疾病的用途。
-
公开(公告)号:US09328104B2
公开(公告)日:2016-05-03
申请号:US14093812
申请日:2013-12-02
Applicant: Pfizer Inc.
Inventor: James Thomas Anderson , Eugene Lvovich Piatnitski Chekler , Edmund L. Ellsworth , Bruce Kipp Erickson , Adam Matthew Gilbert , Anthony P. Ricketts , David P. Thompson , Rayomand Jal Unwalla , Patrick Robert Verhoest
IPC: C07D207/08 , C07D211/22 , C07D217/26 , C07D285/10 , C07D401/04 , C07D417/04 , C07C255/59 , C07C255/58 , C07D205/04
CPC classification number: C07D417/04 , C07C255/58 , C07C255/59 , C07D205/04 , C07D207/08 , C07D211/22 , C07D217/26 , C07D285/10 , C07D401/04
Abstract: The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R1 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1-C6 linear or branched chain alkyl, etc.; R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; Q is —CO—, —(CH2)q—, —(CHRs)q—, or —(CRsRt)q—, where Rs and Rt are independently C1-C6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.
Abstract translation: 本发明涉及式1,2或3的化合物:其中A是N或-CR 0-,其中R 0是氢,C 1 -C 6直链或支链烷基等,Z是-CRe-或 - N-,其中Re为氢,C1-C6直链或支链烷基等; R1是氢,C1-C6直链或支链烷基等; R2独立地为氢或C1-C6直链或支链烷基; R3和R4独立地是氢,C1-C6直链或支链烷基等; R5和R6独立地是氢或C1-C6直链或支链烷基等; R8是氢,C1-C6直链或支链烷基等; R9和R10独立地为氢或C1-C6直链或支链烷基等; Q是-CO - , - (CH2)q-, - (CHRs)q-或 - (CRsRt)q-,其中Rs和Rt独立地是C1-C6直链或支链烷基,芳基,烷基芳基,杂芳基或烷基杂芳基 ; 其中q是0,1,2或3; 并且其中n为0,1,2,3,4或5; 或其药学上可接受的盐包含含有这些化合物的组合物; 以及这些化合物在治疗各种疾病,特别是受雄激素受体影响或介导的疾病的用途。
-